Director Euan A. Ashley filed a Form 4 with the SEC on November 3, 2026, disclosing a transfer of 2,389 shares of DexCom Inc. common stock to a family revocable living trust on October 30, 2026.

Key Highlights

  • Transaction date: October 30, 2026, with 2,389 shares of common stock transferred via transaction code G at a price of $0.
  • Recipient: The Ashley Family Revocable Living Trust, of which Ashley and his spouse serve as co-trustees.
  • No consideration: According to the filing, the transfer was made "for no consideration."
  • Direct holdings after transaction: 10,342 shares beneficially owned directly, which include unvested restricted stock units per the filing's footnote.
  • Indirect holdings: 2,389 shares now held indirectly through the Ashley Family Revocable Living Trust.
  • Unvested RSUs noted: The 10,342 figure includes 5,565 RSUs granted May 28, 2026, and 4,777 RSUs granted October 24, 2025, with separate vesting schedules.

DexCom Director Ashley Moves Shares Into Family Trust at No Cost

According to the Form 4 filing, Euan A. Ashley, a director of DexCom Inc. (NASDAQ:DXCM), transferred 2,389 shares of the company's common stock to the Ashley Family Revocable Living Trust on October 30, 2026. The transaction was recorded under transaction code G and carried a stated price of $0, as the filing specifies the shares were conveyed "for no consideration." Ashley and his spouse are identified as co-trustees of the trust.

Following the reported transaction, the filing states Ashley directly holds 10,342 shares. The filing's footnote clarifies that this total includes unvested restricted stock units: 5,565 RSUs granted on May 28, 2026, which are scheduled to vest on "the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders," and 4,777 RSUs granted on October 24, 2025, which "shall vest through October 24, 2028." The 2,389 shares transferred to the trust are reported as an indirect holding.

The Form 4 was signed by Christophe Cantenot as attorney-in-fact for Dr. Euan Ashley and filed on November 3, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

DexCom director Euan A. Ashley disclosed a gift transfer of 2,389 common shares to a family revocable living trust for no consideration on October 30, 2026, leaving him with 10,342 shares held directly and 2,389 held indirectly through the trust.